更新版 1-百时美施贵宝与 Cellares 签订价值 3.8 亿美元的 CAR-T 疗法供应协议

Reuters04-22

((自动化翻译由路透提供，请见免责声明 )) (全文增加细节)

路透社4月22日 - 制药商百时美施贵宝表示，已与合同制造商Cellares签署了一项价值3.8亿美元的协议，在美国、欧盟和日本生产其CAR-T细胞疗法。

由于需求不断增长，这项合作将有助于百时美施贵宝扩大其生产能力。该公司今年 2 月表示，今年将在一些新的国家推出 CAR-T 血液癌症疗法 Abecma 和 Breyanzi。

CAR-T疗法包括移除患者自身的T细胞--免疫系统的一个关键组成部分--对其进行工程改造，使其能够识别和攻击恶性细胞，然后重新注入。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2429070942?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-22 19:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2429070942","market":"us","top_or_hot":-1,"title":"更新版 1-百时美施贵宝与 Cellares 签订价值 3.8 亿美元的 CAR-T 疗法供应协议","media":"Reuters","content":"<html><body><p>((自动化翻译由路透提供，请见免责声明 )) (全文增加细节)</p><p>    路透社4月22日 - 制药商百时美<a href=\"https://laohu8.com/S/BMY\">施贵宝</a>  表示，已与合同制造商Cellares签署了一项价值3.8亿美元的协议，在美国、欧盟和日本生产其CAR-T细胞疗法。</p><p>由于需求不断增长，这项合作将有助于百时美施贵宝扩大其生产能力。该公司今年 2 月表示，今年将在一些新的国家推出 CAR-T 血液癌症疗法 Abecma 和 Breyanzi。</p><p>CAR-T疗法包括移除患者自身的T细胞--免疫系统的一个关键组成部分--对其进行工程改造，使其能够识别和攻击恶性细胞，然后重新注入。 </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>更新版 1-百时美施贵宝与 Cellares 签订价值 3.8 亿美元的 CAR-T 疗法供应协议</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n更新版 1-百时美施贵宝与 Cellares 签订价值 3.8 亿美元的 CAR-T 疗法供应协议\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-22 19:43 北京时间&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>((自动化翻译由路透提供，请见免责声明 )) (全文增加细节)    路透社4月22日 - 制药商百时美施贵宝  表示，已与合同制造商Cellares签署了一项价值3.8亿美元的协议，在美国、欧盟和日本生产其CAR-T细胞疗法。由于需求不断增长，这项合作将有助于百时美施贵宝扩大其生产能力。该公司今年 2 月表示，今年将在一些新的国家推出 CAR-T 血液癌症疗法 Abecma 和 Breyanzi...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4534","symbol_name":"瑞士信贷持仓","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2429070942","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2429070942","pubTimestamp":1713786237,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"((自动化翻译由路透提供，请见免责声明 )) (全文增加细节)    路透社4月22日 - 制药商百时美施贵宝  表示，已与合同制造商Cellares签署了一项价值3.8亿美元的协议，在美国、欧盟和日本生产其CAR-T细胞疗法。由于需求不断增长，这项合作将有助于百时美施贵宝扩大其生产能力。该公司今年 2 月表示，今年将在一些新的国家推出 CAR-T 血液癌症疗法 Abecma 和 Breyanzi。CAR-T疗法包括移除患者自身的T细胞--免疫系统的一个关键组成部分--对其进行工程改造，使其能够识别和攻击恶性细胞，然后重新注入。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4534":"瑞士信贷持仓","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU0882574055.USD":"富达全球健康医疗A ACC","BK4585":"ETF&股票定投概念","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","LU0237698245.USD":"富达环球地产基金A","BK4007":"制药","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","BMY":"施贵宝","BK4559":"巴菲特持仓","BK4588":"碎股","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","BK4022":"陆运","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4230":"旅客陆运","BK4581":"高盛持仓","LU1032466523.USD":"高盛全球多资产收益组合Acc","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","CAR":"安飞士","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","BK4532":"文艺复兴科技持仓","LU1261432733.SGD":"Fidelity World A-ACC-SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC"},"translate_title":"Updated 1-Bristol-Myers Squibb and Cellares Sign US $380 Million CAR-T Therapy Supply Agreement","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMY":1,"CAR":1},"content_text":"((自动化翻译由路透提供，请见免责声明 )) (全文增加细节)    路透社4月22日 - 制药商百时美施贵宝  表示，已与合同制造商Cellares签署了一项价值3.8亿美元的协议，在美国、欧盟和日本生产其CAR-T细胞疗法。由于需求不断增长，这项合作将有助于百时美施贵宝扩大其生产能力。该公司今年 2 月表示，今年将在一些新的国家推出 CAR-T 血液癌症疗法 Abecma 和 Breyanzi。CAR-T疗法包括移除患者自身的T细胞--免疫系统的一个关键组成部分--对其进行工程改造，使其能够识别和攻击恶性细胞，然后重新注入。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2429070942"}